Dronabinol

Drug Profile

Dronabinol

Alternative Names: 9-THC; Delta9-Tetrahydrocannabinol; Deltanyne; Dronabinol inhaled; Elevat; Marinol; NSC-134454; Pulmonary dronabinol - Solvay/Nektar Therapeutics; δ9-tetrahydrobannabinol

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unimed Pharmaceuticals
  • Developer Nektar Therapeutics; Unimed Pharmaceuticals
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia nervosa; Nausea and vomiting
  • Discontinued Migraine

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2005 Phase-II clinical trials in Migraine (Inhalation)
  • 20 May 2005 Data from a media release have been added to the Advances in the Treatment of Nausea and Migraine therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top